CL2016001661A1 - Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes. - Google Patents

Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.

Info

Publication number
CL2016001661A1
CL2016001661A1 CL2016001661A CL2016001661A CL2016001661A1 CL 2016001661 A1 CL2016001661 A1 CL 2016001661A1 CL 2016001661 A CL2016001661 A CL 2016001661A CL 2016001661 A CL2016001661 A CL 2016001661A CL 2016001661 A1 CL2016001661 A1 CL 2016001661A1
Authority
CL
Chile
Prior art keywords
promoter
vectors
dinucleotides
cmv
recombinant proteins
Prior art date
Application number
CL2016001661A
Other languages
English (en)
Inventor
Gutierrez Juan Carlos Aguillon
Sampayo Maria Carmen Molina
Olate Roberto Aquiles Zuñiga
Gonzales Matias Fernando Gutierrez
Muñoz Norberto Andres Collazo
Lobos Jaime Camilo Teneb
Original Assignee
Univ Chile
Ingenieria Orbicorp Ltda
Bph S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile, Ingenieria Orbicorp Ltda, Bph S A filed Critical Univ Chile
Priority to CL2016001661A priority Critical patent/CL2016001661A1/es
Publication of CL2016001661A1 publication Critical patent/CL2016001661A1/es
Priority to EP17818793.6A priority patent/EP3495487B1/en
Priority to US16/314,192 priority patent/US11618904B2/en
Priority to PCT/CL2017/050024 priority patent/WO2018000105A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL CAMPO DE LA INGENIERIA GENÉTICA, PREFERENTEMENTE LA EXPRESIÓN DE PROTEINAS RECOMBINANTES (PR). PARTICULARMENTE, LA INVENCION SE RELACIONA CON UN PROMOTOR Y SUS VARIANTES QUE TIENEN IGUAL FUNCION Y TIENEN MÀS DEL 90% DE IDENTIDAD DE SECUENCIA 5. EL PROMOTOR COMPRENDE UN FRAGMENTO DE 1147 PARES DE BASES (PB) DE UN PRIMER PROMOTOR, PROMOTOR DEL GEN DE ß-ACTINA DEL GENOMA DE Cricetulus griseus, RICA EN DINUCLEOTIDOS CITOCINA GUANINA (RegCG), QUE PUEDE ESTAR RIO ARRIBA DE UN SEGUNDO PROMOTOR, PROMOTOR DE CITOMEGALOVIRUS (CMV). LA INVENCIÔN TAMBIÉN COMPRENDE VECTORES, LINEAS CELULARES TRANSFECTADAS, Y MÉTODO PARA LA PRODUCCIÓN DE PR, EN CÉLULAS DE MAMIFEROS, LAS QUE HAN SIDO TRANSFECTADAS CON VECTORES QUE CONTIENEN EL PROMOTOR ANTES MENCIONADO O SUS VARIANTES.
CL2016001661A 2016-06-29 2016-06-29 Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes. CL2016001661A1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CL2016001661A CL2016001661A1 (es) 2016-06-29 2016-06-29 Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.
EP17818793.6A EP3495487B1 (en) 2016-06-29 2017-06-09 Promoter with a region rich in cytosine-guanine dinucleotides, vectors, cellular lines, method for producing recombinant protein
US16/314,192 US11618904B2 (en) 2016-06-29 2017-06-09 Promoter with an enriched Cytosine-Guanine dinucleotide region, vectors, cellular lines, method for producing recombinant protein
PCT/CL2017/050024 WO2018000105A1 (es) 2016-06-29 2017-06-09 Promotor con region rica en dinocleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteína recombinante

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2016001661A CL2016001661A1 (es) 2016-06-29 2016-06-29 Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.

Publications (1)

Publication Number Publication Date
CL2016001661A1 true CL2016001661A1 (es) 2017-03-03

Family

ID=60783108

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001661A CL2016001661A1 (es) 2016-06-29 2016-06-29 Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes.

Country Status (4)

Country Link
US (1) US11618904B2 (es)
EP (1) EP3495487B1 (es)
CL (1) CL2016001661A1 (es)
WO (1) WO2018000105A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12582726B1 (en) 2019-04-05 2026-03-24 Earli Inc. Synthetic cancer-specific promoters
CN113564193B (zh) * 2021-09-27 2022-03-11 清华大学 一种微生物基因表达命运共同体及其构建方法和应用
WO2025019712A1 (en) * 2023-07-18 2025-01-23 Earli Inc. Synthetic cancer-specific promoters

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512483A (en) * 1993-05-21 1996-04-30 Mcgill University Expression vectors responsive to steroid hormones
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
PT2332972T (pt) 2003-06-24 2018-04-17 Genzyme Corp Novos promotores de beta-actina e rps21 e suas utilizações
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
ATE546464T1 (de) 2006-04-21 2012-03-15 Agency Science Tech & Res Verfahren zur produktion von rekombinantem protein in cho-zellen
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2010141924A2 (en) * 2009-06-05 2010-12-09 The General Hospital Corporation Enhanced engineered native promoters and uses thereof
CL2010000019A1 (es) 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
KR101038126B1 (ko) 2010-11-30 2011-05-31 주식회사 엘지생명과학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
SG191246A1 (en) 2010-12-24 2013-07-31 Agency Science Tech & Res Modified human cmv promoters that are resistant to gene silencing
CA2832095A1 (en) 2011-04-05 2012-10-11 The Scripps Research Institute Chromosomal landing pads and related uses
GB201315714D0 (en) 2013-09-04 2013-10-16 Fujifilm Diosynth Biotechnologies Uk Ltd DNA Construct
EP3666287A1 (en) 2013-12-31 2020-06-17 ProteoNic Biotechnology IP B.V. Construct and sequence for enhanced gene expression
CA2965202C (en) 2014-10-23 2023-02-28 Sanofi Novel selection marker for cell transfection and protein production
IL258538B2 (en) 2015-10-09 2023-04-01 Genzyme Corp Early isolation after the infection of cells (epic) for the production of biological material

Also Published As

Publication number Publication date
US20190309323A1 (en) 2019-10-10
US11618904B2 (en) 2023-04-04
EP3495487B1 (en) 2026-04-29
WO2018000105A1 (es) 2018-01-04
EP3495487A1 (en) 2019-06-12
EP3495487A4 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
CL2021002741A1 (es) Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de lachnospiraceae bacterium nd2006; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
BR112018004965A2 (pt) domínios de superfamìlia de imunoglobulina variante ajustàvel
MX2022011309A (es) Receptores de celulas t.
BR122021025194A8 (pt) Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna
MX390940B (es) Medio de cultivo celular complementado con taurina y metodos de uso.
MX391337B (es) Sistemas de replicón de arterivirus recombinantes y usos de estos.
EP4368715A3 (en) Nucleic acid sequence analysis from single cells
PY18107830A (es) Variantes de alfa-amilasa y polinucleótidos que las codifican
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
MX2019002938A (es) Mutaciones estebilizantes de trimeros de proteinas de la envoltura del vih.
BR112019010906A2 (pt) polinucleotídeo, vetor, adenovírus, composição, célula, polipeptídeo, uso dos mesmos, e, métodos para induzir e para elicitar uma resposta imune e para profilaxia ou tratamento em um indivíduo.
MX2019008755A (es) Variantes de hsd17b13 y usos de las mismas.
BR112016018598A2 (pt) vetor de vírus adeno-associados
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
BR112022016580A2 (pt) Composições e métodos para induzir uma resposta imune
MX2016014129A (es) Composiciones para el control de mosquitos y usos de las mismas.
MX2023001119A (es) Variantes de enzimas y polinucleotidos que las codifican.
MX2019002307A (es) Anticuerpos multiespecificos que facilitan el emparejamiento selectivo de cadenas ligeras.
MX2020006901A (es) Composiciones de pares de bases no naturales y procedimientos de uso.
CL2017002820A1 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
BR112022026127A2 (pt) Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
CL2018000164A1 (es) Vector recombinante del virus orf.
MX2018007203A (es) Sistema de transposon, kit que comprende el mismo, y sus usos.
CL2021000994A1 (es) Distrofinas miniaturizadas y usos de las mismas
MX382997B (es) Composiciones y metodos para mejorar la expresion genetica de pklr.